129
Views
13
CrossRef citations to date
0
Altmetric
Research Article

8-Oxo-7,8-dihydro-2’-deoxyguanosine, reactive oxygen species and ambulatory blood pressure in African and Caucasian men: The SABPA study

, , , , , , , , , , , & show all
Pages 1291-1299 | Received 13 May 2014, Accepted 24 Jul 2014, Published online: 02 Sep 2014

References

  • Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2009;2:259–269.
  • Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44–84.
  • Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-oxodG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetes. Clin Chim Acta 2004;339:1–9.
  • Zalba G, Beaumont FJ, San José G, Fortuno A, Fortuno MA, Etayo JC, Díez J. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000;35:1055–1061.
  • Jung O, Schreiber JG, Geiger H, Pedrazzini GT, Busse R, Brandes RP. Gp91phox-Containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004;109:1795–1801.
  • Kagota S, Tada Y, Kubota Y, Nejime N, Yamaguchi Y, Nakamura K, et al. Peroxynitrite is involved in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovasc Pharmacol 2007;50:677–685.
  • Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hyptension 2008;51:127–133.
  • Franco MC, Kawamoto EM, Gorjao R, Rastelli VM, Curi R, Scavone C, et al. Biomarkers of oxidative stress and antioxidant status in children born small for gestational age: evidence of lipid peroxidation. Pediatr Res 2007;62:204–208.
  • Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bachler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007;30:1159–1167.
  • Gray K, Bennett M. Role of DNA damage in atherosclerosis – bystander or participant? Biochem Pharmacol 2011;82: 693–700.
  • Hinokio Y, Suzuki S, Hirai M, Suzuki C, Suzuki M, Toyota T. Urinary excretion of 8-oxo-7, 8-dihydro-2’-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002;45:877–882.
  • Negishi H, Njelekela M, Ikeda K, Sagara M, Noguchi T, Kuga S, et al. Assessment of in vivo oxidative stress in hypertensive rats and hypertensive subjects in Tanzania, Africa. Hypertens Res 2000;23(3):285–289.
  • Negishi H, Ikeda K, Kuga S, Noguchi T, Kanda T, Njelekela M, et al. The relation of oxidative DNA damage to hypertension and other cardiovascular factors in Tanzania. J Hypertens 2001;19(3):529–533.
  • Subash P, Gurumurthy P, Sarasabharathi A, Cherian KM. Urinary 8-oxodG: A marker of oxidative stress to DNA and total antioxidant status in essential hypertension with South Indian population. Indian J Clin Biochem 2010;25:127–132.
  • Van Rooyen JM, Kruger HS, Huisman HW, Wissing MP, Margetts BM, Venter CS, Vorster HH. An epidemiological study of hypertension and its determinants in a population in transition: the THUSA study. J Hum Hypertens 2000;14: 779–787.
  • Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008;371:915–922.
  • Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, et al. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol 2012;41:1114–1123.
  • Kruger R, Schutte R, Huisman HW, Van Rooyen JM, Malan NT, Fourie CM, et al. Associations between reactive oxygen species, blood pressure and arterial stiffness in black South-Africans: the SABPA study. J Hum Hypertens 2012; 26:91–97.
  • Schutte R, Schutte AE, Huisman HW, Van Rooyen JM, Malan NT, Szabolcs P, et al. Blood glutathione and subclinical atherosclerosis in African men: The SABPA study. Am J Hypertens 2009;22:1154–1159.
  • Hojo Y, Noma S, Ohki T, Nakajima H, Satoh Y. Autonomic nervous system activity in essential hypertension: a comparison between dippers and non-dippers. J Hum Hypertens 1997;11:665–671.
  • International Society for the advancement of Kinanthropometry (ISAK): International standards for anthropometric assessment, Adelaide; National library of Australia 2001.
  • Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Hypertension 1995;26:808–814.
  • Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281–1357.
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
  • Hayashi I, Morishita Y, Imai K, Nakamura M, Nakachi K, Hayashi T. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res 2007;631: 55–61.
  • Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996;239:70–76.
  • Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA, Wu KY. Comparison of analyses of urinary 8-hydroxy-2’-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom 2004;18:505–510.
  • Saude EJ, Adamko D, Rowe BH, Marrie T, Sykes BD. Variation of metabolites in normal human urine. Metabolomics 2007;3:439–451.
  • Huang H, Helzlsouer KJ, Appel LJ. The effects of Vitamin C and Vitamin E on oxidative DNA damage: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2000;9:647–652.
  • Morris AA, Zhao L, Patel RS, Jones DP, Ahmed Y, Stoyanova N, et al. Differences in systemic oxidative stress based on race and the metabolic syndrome: the Morehouse and Emroy Team up to Eliminate Health Disparities (META-Health) Study. Metab Syndr Relat Disord 2012;10:252–259.
  • Goa R, Price DK, Sissung T, Reed E, Figg WD. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 2008;7:1246–1250.
  • Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096–1101.
  • Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol Med 2011;51:327–336.
  • Calabrese EJ. Hormesis: changing view of the dose–response, a personal account of the history and current status. Mutat. Res 2002;511:181–189.
  • Fukushima S, Kinoshita A, Puatanachokchai R, Kushida M, Wanibuchi H, Morimura K. Hormesis and dose- response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens. Carcinogenesis 2006;26:1835–1845.
  • Ahmad A, Singhal U, Hossain MM, Islam N, Rizvi I. The role of the endogenous antioxidant enzymes and malondialdehyde in essential hypertension. J Clin Diagn Res 2013;7:987–990.
  • Rybka J, Kupczyk D, Kedziora-Kornatowska K, Motyl J, Czuczejko J, Szewczyk-Golec K, et al. Glutathione-related antioxidant defense system in elderly patients treated for hypertension. Cardiovasc Toxicol 2011;11:1–9.
  • Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 2006;20:149–155.
  • Wood RD, Mitchell M, Lindahl T. Human DNA repair genes. Mutat Res 2005;577:275–283.
  • Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002;106:927–932.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.